For research use only. Not for therapeutic Use.
Fosfluconazole（Cat No.:I002485）is a prodrug of fluconazole, an antifungal agent used to treat a variety of fungal infections. It is converted to fluconazole in the body, where it exerts its activity by inhibiting fungal cytochrome P450 enzymes, particularly lanosterol demethylase, disrupting the synthesis of ergosterol, a critical component of fungal cell membranes. This leads to fungal cell death. Fosfluconazole is primarily used in the treatment of systemic fungal infections, including candidiasis and cryptococcosis, offering an alternative to traditional fluconazole with improved pharmacokinetics and oral bioavailability.
| Catalog Number | I002485 |
| CAS Number | 194798-83-9 |
| Molecular Formula | C13H13F2N6O4P |
| Purity | ≥95% |
| Target | Fungal |
| Solubility | DMSO: ≤ 6.2 mg/mL (Need ultrasonic and warming) |
| Storage | 3 years -20℃ powder |
| IUPAC Name | [2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-yl] dihydrogen phosphate |
| InChI | InChI=1S/C13H13F2N6O4P/c14-10-1-2-11(12(15)3-10)13(25-26(22,23)24,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9H,4-5H2,(H2,22,23,24) |
| InChIKey | GHJWNRRCRIGGIO-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)OP(=O)(O)O |
| Reference | </br>1:Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin. Hagiya H, Kajioka H.Intern Med. 2013;52(18):2139-43. PMID: 24042529 Free Article</br>2:Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. Aoyama T, Hirata K, Hirata R, Yamazaki H, Yamamoto Y, Hayashi H, Matsumoto Y.J Clin Pharm Ther. 2012 Jun;37(3):356-63. doi: 10.1111/j.1365-2710.2011.01297.x. Epub 2011 Aug 24. PMID: 21883330 </br>3:[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]. Sawada A, Sakata N, Higuchi B, Takeshita Y, Ishihara T, Sakata A, Kouroki M, Kondo O, Koyama M, Hirano S, Yasui M, Inoue M, Yoshioka A, Kawa K.Rinsho Ketsueki. 2009 Dec;50(12):1692-9. Japanese. PMID: 20068276 </br>4:Fosfluconazole for antifungal prophylaxis in very low birth weight infants. Takahashi D, Nakamura T, Shigematsu R, Matsui M, Araki S, Kubo K, Sato H, Shirahata A.Int J Pediatr. 2009;2009:274768. doi: 10.1155/2009/274768. Epub 2009 Apr 23. PMID: 19946419 Free PMC Article</br>5:Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Aoyama T, Ogata K, Shimizu M, Hatta S, Masuhara K, Shima Y, Kimura K, Matsumoto Y.Drug Metab Pharmacokinet. 2005 Dec;20(6):485-90. PMID: 16415533 Free Article</br>6:The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Sobue S, Tan K, Haug-Pihale G.Br J Clin Pharmacol. 2005 Feb;59(2):160-6. PMID: 15676037 Free PMC Article</br>7:[Nonclinical studies and clinical studies on fosfluconazole, a triazole antifungal agent (Prodif)]. Kawakami Y, Nagino K, Shinkai K, Sobue S, Abe M, Ishiko J.Nihon Yakurigaku Zasshi. 2004 Jul;124(1):41-51. Review. Japanese. PMID: 15226621 </br>8:Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. Sobue S, Tan K, Layton G, Eve M, Sanderson JB.Br J Clin Pharmacol. 2004 Jul;58(1):20-5. PMID: 15206988 Free PMC Article</br>9:The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Sobue S, Tan K, Layton G, Leclerc V, Weil A.Br J Clin Pharmacol. 2004 Jun;57(6):773-84. PMID: 15151523 Free PMC Article</br>10:Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers. Sobue S, Tan K, Shaw L, Layton G, Hust R.Eur J Clin Pharmacol. 2004 Jun;60(4):247-53. Epub 2004 Apr 22. PMID: 15103438 |
